OncLive SOSS

New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 1

Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

June 25, 2024

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center, Frederick L. Locke, MD, Moffitt Cancer Center

Medical experts highlight second-line options for treating patients with DLBCL.

EP. 1: Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP. 2: Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

Video content above is prompted by the following:

Please discuss the NCCN-preferred second-line treatments for patients with DLBCL.
- For those with intent to proceed to transplant.
  - Primary refractory or early relapse (< 12 months after first-line therapy).
- Late relapse (> 12 months after 1L therapy).
- For those with no intent to proceed to transplant.
- Primary refractory or relapse.